<![CDATA[Genmab — April 2023]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/topic/399171/genmab-april-2023RSS for NodeSun, 07 Jun 2026 21:39:02 GMTSat, 01 Apr 2023 03:47:49 GMT60<![CDATA[Reply to Genmab — April 2023 on Sat, 29 Apr 2023 05:49:52 GMT]]>Kunne det have relevans i henhold til samarbejdet med ArgenX eller deres nye forretningsområde

]]>https://dev.proinvestor.com/forum/post/7662943https://dev.proinvestor.com/forum/post/7662943Sat, 29 Apr 2023 05:49:52 GMT<![CDATA[Reply to Genmab — April 2023 on Sat, 29 Apr 2023 05:10:19 GMT]]>Angående 28/4 15:17: Lidt spekulativt, men det kan jo være, a tde fortsat ser lidt på Zalu, der jo havde relativt gode resultater, men i en kritisk tid for Genmab: "zanolimumab, a human anti-CD4 IgG1 mAb, was harnessing effector functions for the treatment of CD4-expressing malignant T cells in cutaneous T-cell lymphomas (Rider et al., 2007) until development was discontinued during Phase III for what appear to be business-related reasons."

]]>https://dev.proinvestor.com/forum/post/7662946https://dev.proinvestor.com/forum/post/7662946Sat, 29 Apr 2023 05:10:19 GMT<![CDATA[Reply to Genmab — April 2023 on Fri, 28 Apr 2023 11:22:08 GMT]]>similar action in this TV trial as in the Epco trial yesterday; Enrollment enlarged from 482 to 556, China still recruiting https://clinicaltrials.gov/ct2/history/NCT04697628?A=61&B=62&C=Side-by-Side#StudyPageTop

]]>https://dev.proinvestor.com/forum/post/7662942https://dev.proinvestor.com/forum/post/7662942Fri, 28 Apr 2023 11:22:08 GMT<![CDATA[Reply to Genmab — April 2023 on Fri, 28 Apr 2023 11:17:13 GMT]]>why would they bother cleaning up the files in clinicaltrials.gov for trials that ended >10yrs ago? HuMax-CD4 / Zanolimumab https://clinicaltrials.gov/ct2/history/NCT00042406?A=3&B=4&C=merged#StudyPageTop https://clinicaltrials.gov/ct2/history/NCT00071084?A=3&B=4&C=merged#StudyPageTop

]]>https://dev.proinvestor.com/forum/post/7662944https://dev.proinvestor.com/forum/post/7662944Fri, 28 Apr 2023 11:17:13 GMT<![CDATA[Reply to Genmab — April 2023 on Fri, 28 Apr 2023 07:25:30 GMT]]>MedWatch meddeler: Sgen solgte i Q1 for $19Mio, stigning på 67% i Tivdak.

]]>https://dev.proinvestor.com/forum/post/7662938https://dev.proinvestor.com/forum/post/7662938Fri, 28 Apr 2023 07:25:30 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 18:44:44 GMT]]>Fra Børsen "Medicinalgiganten og Novo Nordisk-konkurrenten Eli Lilly opjusterede sine forventninger til hele året i sit regnskab for første kvartal.

Det kvitterede investorerne for med et kursplus på 3,7 pct.

Også medicinalselskabet Merck opjusterede forventningerne i sit regnskab, hvor også indtjeningen var bedre end ventet. Aktien steg 1,5 pct."

]]>https://dev.proinvestor.com/forum/post/7662941https://dev.proinvestor.com/forum/post/7662941Thu, 27 Apr 2023 18:44:44 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 15:58:18 GMT]]>Rally i US men ikke i healthcare, og slet ikke AbbVie.

]]>https://dev.proinvestor.com/forum/post/7662935https://dev.proinvestor.com/forum/post/7662935Thu, 27 Apr 2023 15:58:18 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 12:54:36 GMT]]>small new Dara trial - Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia https://clinicaltrials.gov/ct2/show/NCT05832216?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody+OR+hexabody+OR+Teclistamab+OR+Amivantamab+OR+Talquetamab+OR+Epcoritamab+OR+DuoHexabody&lupd_s=04%2F27%2F2023&draw=2&rank=1

]]>https://dev.proinvestor.com/forum/post/7662936https://dev.proinvestor.com/forum/post/7662936Thu, 27 Apr 2023 12:54:36 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 12:53:45 GMT]]>EPCORE DLBCL-1 ; looks like recruiting is finished in almost all centers, only China still recruiting and at the same time Enrollment enlarged from 480 to 552 https://clinicaltrials.gov/ct2/history/NCT04628494?A=20&B=21&C=merged#StudyPageTop

]]>https://dev.proinvestor.com/forum/post/7662945https://dev.proinvestor.com/forum/post/7662945Thu, 27 Apr 2023 12:53:45 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 12:21:31 GMT]]>Det kan komme, når du mindst venter det.

]]>https://dev.proinvestor.com/forum/post/7662932https://dev.proinvestor.com/forum/post/7662932Thu, 27 Apr 2023 12:21:31 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 11:53:18 GMT]]>Sommeren nærmere sig, og vi skulle jo gerne snart smide sokkerne. Men det bliver jo nok ikke i år, at det bliver med baggrund i Jans KYSO strategi.

]]>https://dev.proinvestor.com/forum/post/7662933https://dev.proinvestor.com/forum/post/7662933Thu, 27 Apr 2023 11:53:18 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 11:40:13 GMT]]>Kort video - Pharma og biotek-opdatering UGE 17: Demant ' GN Store Nord ' Novo Nordisk ' Genmab ' Zealand Pharma ' Hansa Biopharma https://www.proinvestor.com/boards/112327

]]>https://dev.proinvestor.com/forum/post/7662937https://dev.proinvestor.com/forum/post/7662937Thu, 27 Apr 2023 11:40:13 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 11:02:02 GMT]]>Kort video:
Ugekommentar #90 Navigation i et hav af regnskaber - Det vælter ind med kvartalsregnskaber. Helge Larsen fortæller i denne ugekommentar om, hvordan du nemt finder regnskaber fra de selskaber, du interesserer dig for, og hvor du finder gode input i kølvandet på disse regnskaber. https://www.proinvestor.com/boards/112325

]]>https://dev.proinvestor.com/forum/post/7662929https://dev.proinvestor.com/forum/post/7662929Thu, 27 Apr 2023 11:02:02 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 09:34:54 GMT]]>@Sukkeralf - ja der vil henstå mange spørgsmål, som ikke nødvendigvis bliver besvaret fuldstændig. Det gør det ikke mindre uinteressant, at overveje de strategiske konsekvenser. Genmab kan om få år stå i en tilsvarende konflikt med en af sine agentaftaler. Mon Winkel så vil fastholde sin "respektfulde" tilgang eller lade jura og en voldgift afklare en mulig tvist - og nej, tror ikke Jan har lyst til, at svare særlig præcist på sin strategi, hvis han får spørgsmålet serveret.

]]>https://dev.proinvestor.com/forum/post/7662930https://dev.proinvestor.com/forum/post/7662930Thu, 27 Apr 2023 09:34:54 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 09:30:43 GMT]]>2 gode spørgsmål. Mon ikke Google kan give dig svaret hurtigere end du får leveret svaret herinde 🙂

]]>https://dev.proinvestor.com/forum/post/7662931https://dev.proinvestor.com/forum/post/7662931Thu, 27 Apr 2023 09:30:43 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 09:27:46 GMT]]>Hvad var kursen da voldgiftsagen startet? Og hvor mange år er der gået med den nu:-)?

]]>https://dev.proinvestor.com/forum/post/7662934https://dev.proinvestor.com/forum/post/7662934Thu, 27 Apr 2023 09:27:46 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 09:02:34 GMT]]>Tak @gentogen . Jeg tror nærmere ca. 9 mdr. Men håber, du har ret 😉

]]>https://dev.proinvestor.com/forum/post/7662940https://dev.proinvestor.com/forum/post/7662940Thu, 27 Apr 2023 09:02:34 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 08:49:23 GMT]]>Ikke at man bliver meget klogere, men mon ikke det er maks. 5 måneder

]]>https://dev.proinvestor.com/forum/post/7662928https://dev.proinvestor.com/forum/post/7662928Thu, 27 Apr 2023 08:49:23 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 08:48:30 GMT]]>The Party seeking review must submit its opening brief and any reply brief within [] and [] calendar days, respectively, following the date of the award under review, whereas the opposing Party must submit its responsive brief within [] calendar days of that date. Oral argument shall take place within [] calendar months after the date of the award under review, and the Appeal Arbitrator shall render a decision within [***] calendar days following oral argument.

]]>https://dev.proinvestor.com/forum/post/7662927https://dev.proinvestor.com/forum/post/7662927Thu, 27 Apr 2023 08:48:30 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 07:36:55 GMT]]>Vi nærmer os sommer od sol - men Genmab aktien må jo nok leve i voldgiftens skygge en rum tid endnu. Er der nogen, der har kendskab til varigheden af behandling af en anke?

]]>https://dev.proinvestor.com/forum/post/7662924https://dev.proinvestor.com/forum/post/7662924Thu, 27 Apr 2023 07:36:55 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 06:19:06 GMT]]>😉

]]>https://dev.proinvestor.com/forum/post/7662923https://dev.proinvestor.com/forum/post/7662923Thu, 27 Apr 2023 06:19:06 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 06:13:06 GMT]]>Oh, by that time dara patent has run out 😉 almost.

]]>https://dev.proinvestor.com/forum/post/7662922https://dev.proinvestor.com/forum/post/7662922Thu, 27 Apr 2023 06:13:06 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 06:06:57 GMT]]>no; they have it in their Expected submission timeline in '2025 and beyond' https://www.sanofi.com/dam/jcr:a47dcb49-3067-44bc-9cd1-dc1fd0094b66/2023_04_27_Sanofi_Q1_2023_Results_Presentation.pdf

]]>https://dev.proinvestor.com/forum/post/7662926https://dev.proinvestor.com/forum/post/7662926Thu, 27 Apr 2023 06:06:57 GMT<![CDATA[Reply to Genmab — April 2023 on Thu, 27 Apr 2023 06:00:36 GMT]]>Still not sc. As far as I can see. Study started last year. https://clinicaltrials.gov/ct2/show/NCT05405166

]]>https://dev.proinvestor.com/forum/post/7662920https://dev.proinvestor.com/forum/post/7662920Thu, 27 Apr 2023 06:00:36 GMT